These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31130319)

  • 1. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
    Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
    Health Policy; 2019 Jul; 123(7):630-634. PubMed ID: 31130319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
    Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
    Health Policy; 2019 Aug; 123(8):713-720. PubMed ID: 31277882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
    Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
    Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study.
    Abdallah K; Claes K; Huys I; Follon L; Calis C; Simoens S
    Orphanet J Rare Dis; 2022 Dec; 17(1):429. PubMed ID: 36494733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review.
    Beck A; Retèl VP; Bhairosing PA; van den Brekel M; van Harten WH
    Health Policy; 2019 Dec; 123(12):1185-1198. PubMed ID: 31718855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 12. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers.
    Enzing JJ; Himmler S; Knies S; Brouwer WBF
    Value Health; 2022 Feb; 25(2):222-229. PubMed ID: 35094795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
    Van Wilder P; Pirson M; Dupont A
    Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist.
    Moen E; Toverud EL; Grund J; Brinchmann S
    Pharm World Sci; 1998 Jun; 20(3):107-12. PubMed ID: 9618733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model.
    Nuijten MJ; Kosa J
    Eur J Health Econ; 2004 Jun; 5(2):110-5. PubMed ID: 15452745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to medicines for rare diseases: A European regulatory roadmap for academia.
    Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM
    Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.